三组不同联合化疗方案治疗晚期非小细胞肺癌  

A comparison of the effects of three chemotherapy regimens for advanced non small cell lung cancer

作　　者：张沂平[1] 徐农[1] 孙琳[1] 郭根法[1] 蔡菊芬[1] 钟海均[1] 范云[1] 

机构地区：[1]浙江省肿瘤医院化疗中心,浙江杭州310022

出　　处：《中国癌症杂志》2000年第6期514-516,共3页China Oncology

摘　　要：目的 :观察比较TP(Taxol、DDP) ,MNP(MMC、NVB、DDP)和MVP(MMC、VDS、DDP)联合化疗治疗晚期非小细胞肺癌的近期疗效和耐受性。方法 :110例晚期非小细胞肺癌接受三种不同化疗方案治疗 ,TP组 2 7例 ,MNP组40例 ,MVP组 43例。结果 :TP组有效率 5 1 9% ,中位缓解期 9 0个月 ,中位生存期 11 2个月 ;MNP组有效率为45 0 % ,中位缓解期 8 0个月 ,中位生存期 10 5个月 ;MVP组有效率 32 6 % ,中位缓解期 6 8个月 ,中位生存期 8 1个月。TP、MNP方案有效率高于MVP方案 ,但统计学无显著差异。主要毒性为骨髓抑制、恶心呕吐和脱发。结论 :本研究结果表明 ,泰素加顺铂治疗晚期非小细胞肺癌疗效较好 ,毒性反应可耐受 ,是目前治疗NSCLC的首选方案之一。Purpose:To compare taxol,cisplatin(TP) and mitomycin, vinorelbine and cisplatin (MNP) with mitomycin,vindesine and cisplatin (MVP) and to evaluate the efficacy of the three regimens in patients with advanced non small cell lung cancer (NSCLC).Methods: One hundred and ten patients were enrolled in this study, 27 on TP, 40 on MNP and 43 on MVP. The characteristics of patients were comparable.Results:An objective response rate was observed in 51.9% of patients in the TP arm, 45.0% of patients in the MNP arm versus 32.6% in the MVP arm. The median duration of survival was 11.2 months in the TP arm, compared with 10.5 months in the MNP arm and 8.1 months in the MVP arm. The progression free survival was 9.0 months、8.0 months and 6.8 months in the TP、MNP and MVP arms, respectively. The major toxicities were bone marrow suppression、nausea、vomiting and alopecia.Conclusions:TP had a higher response rate than MNP and MVP, with acceptable toxicity. Its efficacy should be confirmed through a randomized study.

关 键 词：晚期非小细胞肺癌 药物治疗 TP方案 MNP方案 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]